Pasar al contenido principal

Re-educating tumor associated macrophages with nanoparticle emulsions to reduce tumor burden and met

FJC2020-044220-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Juan de la Cierva Formación
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells

  • López-Gil, Juan Carlos
  • García-Silva, Susana
  • Ruiz-Cañas, Laura
  • Navarro, Diego
  • Palencia-Campos, Adrián
  • Giráldez-Trujillo, Antonio
  • Earl, Julie
  • Dorado, Jorge
  • Gómez-López, Gonzalo
  • Monfort-Vengut, Ana
  • Alcalá, Sonia
  • Gaida, Matthias M.
  • García-Mulero, Sandra
  • Cabezas-Sainz, Pablo
  • Batres-Ramos, Sandra
  • Barreto, Emma
  • Sánchez-Tomero, Patricia
  • Vallespinós, Mireia
  • Ambler, Leah
  • Lin, Meng-Lay
  • Aicher, Alexandra
  • García García de Paredes, Ana
  • Pinta, Carolina De La
  • Sanjuanbenito, Alfonso
  • Ruz-Caracuel, Ignacio
  • Rodríguez-Garrote, Mercedes
  • Guerra, Carmen
  • Carrato, Alfredo
  • Cárcer, Guillermo de
  • Sánchez, Laura
  • Nombela-Arrieta, César
  • Espinet, Elisa
  • Sánchez-Arévalo Lobo, Víctor J.
  • Heeschen, Christopher
  • Sainz, Bruno Jr.
[Objective]: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant ‘stem-like’ cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies., [Design]: We used the KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and primary tumour cell lines to investigate putative CSC populations. Transcriptomic analyses were conducted to pinpoint new genes involved in immune evasion. Overexpressing and knockout cell lines were established with lentiviral vectors. Subsequent in vitro coculture assays, in vivo mouse and zebrafish tumorigenesis studies, and in silico database approaches were performed., [Results]: Using the KPC mouse model, we functionally confirmed a population of cells marked by EpCAM, Sca-1 and CD133 as authentic CSCs and investigated their transcriptional profile. Immune evasion signatures/genes, notably the gene peptidoglycan recognition protein 1 (PGLYRP1), were significantly overexpressed in these CSCs. Modulating PGLYRP1 impacted CSC immune evasion, affecting their resistance to macrophage-mediated and T-cell-mediated killing and their tumourigenesis in immunocompetent mice. Mechanistically, tumour necrosis factor alpha (TNFα)-regulated PGLYRP1 expression interferes with the immune tumour microenvironment (TME) landscape, promoting myeloid cell-derived immunosuppression and activated T-cell death. Importantly, these findings were not only replicated in human models, but clinically, secreted PGLYRP1 levels were significantly elevated in patients with PDAC., [Conclusions]: This study establishes PGLYRP1 as a novel CSC-associated marker crucial for immune evasion, particularly against macrophage phagocytosis and T-cell killing, presenting it as a promising target for PDAC immunotherapy., JCL-G received support from a ’la Caixa’ Foundation (ID 100010434) fellowship (LCF/BQ/DR21/11880011) and an EMBO Scientific Exchange Fellowship (ID 10210). AP-C was a recipient of a Juan de la Cierva Formación 2020 (FJC2020- 044220-I) grant. This study was supported by a Fero Foundation Grant (BSJr.) and Rámon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economía y Competitividad, Spain (BSJr.); received funding from the Beca Carmen Delgado/ Miguel Pérez-Mateo from AESPANC-ACANPAN Spain (BSJr), a Conquer Cancer Now Grant from the Concern Foundation (Los Angeles, CA, USA) (BSJr), a Coordinated grant (GC16173694BARB) from the Fundación Asociación Española Contra el Cáncer (AECC) (BSJr; AC), and FIS grants PI18/00757 and PI21/01110 (BSJr), PI19/00514 (CG) and PI22/00492 (VJSAL); and cofinanced through Fondo Europeo de Desarrollo Regional ’Una manera de hacer Europa’). We also acknowledge the support from CIBERONC (CB16/12/00446) (AC) and Ayudas de Consolidación y Estructuración de grupos from Consellería de Educación, Universidade y Formación profesional (ED431C-2028/28) and Programa de axudas á etapa posdotoral, both from Xunta de Galicia (LS, PCS). Projects were financed via MCIN/ AEI/FEDER (10.13039/501100011033) (REF-PID2021-125705OB-I00 (GdC) and REF-RTI2018- 095496-B-100) (GdC), and PID2021-124520OA-I00 and RYC2020-029767 (EE), and others including AECC (LABAE16017DECÁ, GdC and TRNSC213893ESPI, SG-M); the Clinical Research Priority Program ’ImmunoCure’ of the University of Zurich (CN-A), the German Research Foundation (SFB1292 Project Number 318346496, TPQ1 and TP22), GA1818/2-3 (MMG) as well as funding from an ERC Advanced Investigator Grant (Pa-CSC 233460, CH), the European Community’s Seventh Framework Programme (FP7) under grant agreement n° 602783 (CAM-PaC, CH), the Fondazione del Piemonte per l’Oncologia – IRCCS (PTCRC-Intra-2021, CH), the Fondazione AIRC per la ricerca sul cancro (IG 2023 ID 28933, CH), the Shanghai Municipal Education Commission (2021-01-07-00-02-E00090, CH), and the National Science Foundation China (82130074, CH)., Peer reviewed